Accuray Inc (ARAY)
1.815
+0.02
(+1.40%)
USD |
NASDAQ |
Jun 28, 16:00
1.82
0.00 (0.00%)
After-Hours: 20:00
Accuray Research and Development Expense (TTM): 54.39M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 54.39M |
| December 31, 2023 | 57.69M |
| September 30, 2023 | 57.05M |
| June 30, 2023 | 57.13M |
| March 31, 2023 | 57.51M |
| December 31, 2022 | 57.41M |
| September 30, 2022 | 57.46M |
| June 30, 2022 | 57.75M |
| March 31, 2022 | 58.54M |
| December 31, 2021 | 57.70M |
| September 30, 2021 | 54.96M |
| June 30, 2021 | 52.73M |
| March 31, 2021 | 49.59M |
| December 31, 2020 | 47.48M |
| September 30, 2020 | 48.59M |
| June 30, 2020 | 49.78M |
| March 31, 2020 | 53.62M |
| December 31, 2019 | 55.37M |
| September 30, 2019 | 55.94M |
| June 30, 2019 | 56.49M |
| March 31, 2019 | 55.03M |
| December 31, 2018 | 56.02M |
| September 30, 2018 | 57.05M |
| June 30, 2018 | 57.25M |
| March 31, 2018 | 55.93M |
| Date | Value |
|---|---|
| December 31, 2017 | 54.50M |
| September 30, 2017 | 51.78M |
| June 30, 2017 | 49.92M |
| March 31, 2017 | 50.81M |
| December 31, 2016 | 51.60M |
| September 30, 2016 | 54.58M |
| June 30, 2016 | 56.65M |
| March 31, 2016 | 57.35M |
| December 31, 2015 | 56.91M |
| September 30, 2015 | 55.90M |
| June 30, 2015 | 55.75M |
| March 31, 2015 | 54.48M |
| December 31, 2014 | 55.40M |
| September 30, 2014 | 54.92M |
| June 30, 2014 | 53.72M |
| March 31, 2014 | 54.84M |
| December 31, 2013 | 56.77M |
| September 30, 2013 | 60.57M |
| June 30, 2013 | 66.20M |
| March 31, 2013 | 73.00M |
| December 31, 2012 | 79.70M |
| September 30, 2012 | 80.74M |
| June 30, 2012 | 82.73M |
| March 31, 2012 | 75.90M |
| December 31, 2011 | 62.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
47.48M
Minimum
Dec 2020
58.54M
Maximum
Mar 2022
54.86M
Average
56.22M
Median
Research and Development Expense (TTM) Benchmarks
| Boston Scientific Corp | 1.444B |
| Perspective Therapeutics Inc | 24.91M |
| ResMed Inc | 304.81M |
| Glaukos Corp | 134.32M |
| Xtant Medical Holdings Inc | 1.689M |